Profusa (NASDAQ:PFSA) Stock Scheduled to Reverse Split on Monday, August 17th

Profusa, Inc. (NASDAQ:PFSA)’s stock is scheduled to reverse split on the morning of Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 16th.

Profusa Stock Performance

Shares of PFSA traded down $0.01 during midday trading on Thursday, hitting $0.95. The company had a trading volume of 197,899 shares, compared to its average volume of 224,255. The company’s 50-day simple moving average is $2.85 and its 200-day simple moving average is $25.06. The firm has a market capitalization of $180,614.00, a P/E ratio of -0.00 and a beta of 0.52. Profusa has a 1 year low of $0.81 and a 1 year high of $1,297.50.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a report on Wednesday, June 24th. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Profusa currently has a consensus rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.